Rayner has received FDA 510(k) clearance for its Sophi phacoemulsification system.

Sophi—short for Swiss Ophthalmology Innovation—is designed to combine advanced technology with streamlined usability. It is built to meet the needs of ambulatory surgery centers (ASCs), office-based surgery settings, and US hospital networks.

Key features include: Triple Pump Fluidics, offering both peristaltic and venturi options; an intuitive user interface; and a wireless power concept that enhances flexibility and mobility. Together, these innovations are engineered to support faster setup, improved workflow efficiency, quicker patient turnover, and enhanced mobility for clinical teams—while maintaining the highest standards of patient safety, according to Rayner.

“Sophi has been my only phaco machine for the past 4 years,” said Dr. Erik Mertens, Medical Director at Medipolis in Belgium and Past-President of AECOS Europe. “Its fluidics, ease of use and versatility truly set it apart. I highly recommend it to high-volume cataract and refractive surgeons.”

Beyond performance and efficiency, Sophi is also designed with the future of sustainable ophthalmology in mind. A recent multisociety position paper from ophthalmic organizations—including ASCRS, ESCRS, APACRS, and LATAMSCRS—estimated a 307 kg reduction in discarded plastic per 1,000 cataract surgeries when using Sophi’s day cassette option. 

“US surgeons deserve an innovative alternative to conventional phaco technology, and Sophi delivers that," said Rayner CEO Tim Clover. "Clinics worldwide tell us they’re running more efficiently and cutting cost and waste, so we’re looking forward to bringing these benefits to surgeons across the US through our new team of surgical equipment specialists.”

For more information, surgeons are encouraged to contact their local Rayner representative or click here.